Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers

International Journal of Cardiology

Volumn 62, Issue SUPPL. 2, 1997, Pages

  Schachter, Michael ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Calcium channel blockers; Cell migration; Vascular smooth muscle cell

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BB;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DNA SYNTHESIS; DRUG EFFECT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

AMLODIPINE; ARTERIOSCLEROSIS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCLE, SMOOTH, VASCULAR;

EID: 0031593038     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00245-3     Document Type: Conference Paper

References (35)

1. Fleckenstein A., Frey M., Zorn J., Fleckenstein-Grun G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends Pharmacol Sci. 8:1987;496-501.
2. Weinstein D.B., Heider J.G. Antiatherogenic properties of calcium antagonists. Am J Cardiol. 59(Suppl):1987;163B-172B.
3. Triggle D.J. Calcium antagonists in atherosclerosis: a review and commentary. Cardiovasc Drug Revs. 6:1989;320-335.
4. Keogh A.M., Schroeder J.S. A review of calcium antagonists and atheroclerosis. J Cardiovasc Pharmacol. 16(Suppl 6):1990;S28-S35.
5. 2+ channel blockers. Atherosclerosis. 88:1991;109-132.
6. Borcherding S.M., Meeves S.G., Klutman N.E., Howard P.A. Calcium-channel antagonists for prevention of atherosclerosis. Ann Pharmacother. 27:1993;61-67.
7. Waters D., Lespérance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J. 128:1994;1309-1316.
8. Jackson C.L., Bush R.C., Bowyer D.E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis. 80:1989;17-26.
9. Henry P.D. Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action. Cardiovasc Drugs Ther. 4:1990;1015-1020.
10. Schwartz S.M., deBlois D., O'Brien E.R.M. The Intima. Soil for atherosclerosis and restenosis. Circ Res. 77:1995;445-465.
11. Raines E.W., Ross R. Smooth muscle cells and the pathogenesis of the lesions of atherosclerosis. Br Heart J. 69(Suppl):1993;S30-S37.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
13. Stein O., Stein Y. Smooth muscle cells and atherosclerosis. Current Opin Lipidol. 6:1995;269-274.
14. Witztum J.L. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J, 69(Suppl):1993;S12-S18.
15. Campbell G.R., Campbell J.H. The phenotypes of smooth muscle expressed in human atheroma. Ann NY Acad Sci. 598:1990;143-158.
16. Abedi H., Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res. 30:1995;544-556.
17. Bornfeldt K.E. Intracellular signaling in arterial smooth muscle migration versus proliferation. Trends Cardiovasc Med. 6:1996;143-151.
18. Bornfeldt K.E., Raines E.W., Nakano T., Graves L.M., Krebs E.G., Ross R. Insulin-like growth factor I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 93:1994;1266-1274.
19. 2+ transients are not required for platelet-derived growth factor to induce cell cycle progression of vascular smooth muscle cells in primary culture. J Biol Chem. 269:1994;9011-9018.
20. Mogami H., Kojima I. Stimulation of calcium entry prerequisite for DNA synthesis induced by platelet-derived growth factor in vascular smooth muscle cells. Biochem Biophys Res Comm. 196:1993;650-658.
21. Bilato C., Pauly R.R., Melillo R.et al. Intracellular signaling pathways required for rat vascular smooth muscle cell migration. Interactions between basic fibroblast growth factor and platelet-derived growth factor. J Clin Invest. 96:1995;1905-1915.
22. Pauly R.R., Bilato C., Sollott S.J.et al. Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation. 91:1995;1107-1115.
23. Homma Y., Sakamoto H., Tsunoda M., Aoki M., Takenawa T., Ooyama T. Evidence for involvement of phospholipase Cγ2 in signal transduction of platelet-derived growth factor in vascular smooth muscle cells. Biochem J. 290:1993;649-653.
24. Hughes A.D., Clunn G.F., Refson J., Demoliou-Mason C. Platelet derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen Pharmacol. 27:1996;1079-1089.
25. 2+-permeable channel associated with platelet-derived growth factor receptor in mesangial cells. Am J Physiol. 267:1994;C456-C465.
26. Nakao J., Ito H., Ooyama T., Chahng W.C., Murota S. Calcium dependency of aortic smooth muscle cell migration induced by 12-L-hydroxy-5,8,10,14-eiscosatetraenoic acid. Effects of A23187, nicardipine and trifluoperazine. Atherosclerosis. 46:1983;309-319.
27. Nomoto A., Mutoh S., Hagihara H., Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 72:1988;213-219.
28. Corsini A., Qurato P., Raiteri M.et al. Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res. 27:1993;299-307.
29. Bernini F., Soma M.R., Corsini A., Paoletti R. Experimental and clinical effects of isradipine relevant to atherosclerosis. Am J Hypertens. 7:1994;30S-34S.
30. Corsini A., Bonfatti M., Quarato P.et al. Effect of the calcium antagonist lercanidipone and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol. 28:1996;687-694.
31. McMurray H.F., Chahwala S.B. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20(Suppl A):1992;S54-S56.
32. Munro E., Patel M., Chan P.et al. Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J Cardiovasc Pharmacol. 23:1994;779-784.
33. Weissberg P.L., Clesham G.J., Bennett M.R. Is vascular smooth muscle proliferation beneficial? Lancet. 347:1996;305-307.
34. Nelson P.R., Yamamura S., Kent K.C. Extracellular matrix proteins are potent agonists of human smooth muscle cell migration. J Vasc Surg. 24:1996;25-33.
35. Hughes A.D., Schachter M. Multiple pathways for entry of calcium and other divalent cations in a vascular smooth muscle cell line (A7r5). Cell Calcium. 14:1994;317-330.